SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending following a $75 million direct offering to a new institutional investor, igniting intense community debate over whether this strategic funding validates its "best-in-class" MASH drug for a potential partnership, or if it represents desperate dilution. This development, coupled with growing institutional interest, places the company at the center of discussions regarding its future in the competitive MASH sector.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox is trending due to a sharp decline fueled by market concerns over Google's new AI-powered 3D world creation tool and ongoing lawsuits regarding child safety on its platform. This has led to a split in community sentiment, with some viewing it as an "overreaction" and a "buy-the-dip" opportunity given strong user engagement and viral content, while others highlight profitability challenges and the potential impact of new age verification policies.

Fefe is a memecoin inspired by Matt Furie's book "Mindviscosity," published in 2020.  Follow FEFE, the alter ego of PEPE in the book “Mindviscosity” by Matt Furie.  Fefe is a main character in the book, who is a laid back and carefree frog living in a whimsical world. Fefe's relaxed and adventurous spirit captures the heart of this imaginative universe.  Launched stealth with no presale, zero taxes, LP burnt and contract renounced - TAX: 0/0 This narrative has its roots in a fascinating story.  Join us and become part of the $FEFE community today!

Fefe

FEFE CRYPTO is trending due to its passionate community actively pushing the narrative that it's the authentic representation of Pepe the Frog by creator Matt Furie, positioning it as the "Shiba Inu to Pepe's Doge." Despite some vocal skeptics calling it a pump-and-dump, supporters are unwavering, actively building momentum, and driving discussions around its potential as a leading frog-themed memecoin on Ethereum.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

A significant stock drop and massive trading volume are gripping Unity Software after Google unveiled its Project Genie AI model for 3D world creation. The community is sharply divided, with fear of AI disruption countered by arguments that this represents an overreaction and a buying opportunity, as AI could accelerate demand for Unity's core platform ahead of upcoming earnings.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is gaining attention amid expectations for robust Q4 earnings and news of competitor Cotti Coffee ending deep discounts, signaling potential margin improvement. Despite rapid store expansion and perceived undervaluation compared to rivals like Starbucks, the community is actively debating the stock's stalled price action and the ongoing speculation around its uplisting from the OTC market.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending amid active speculation sparked by a reported acquisition interest from Zydus Lifesciences and its "no comment" response, which, alongside recent patent extensions and analyst upgrades, reinforces community discussion about the company's significant undervaluation. This robust M&A chatter is amplified by Ardelyx's extensive hiring for commercial and market access roles, signaling an aggressive push to maximize the sales and market penetration of its key products.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digital is trending following a strong Q2 earnings beat and bullish guidance, which investors are actively discussing as either a buying opportunity driven by persistent AI and data center demand or a sign of an overheated memory sector given its rapid appreciation and initial post-earnings dip.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending after a significant sell-off occurred despite the company reporting robust earnings and raising guidance, sparking intense community discussion about market manipulation to "kill options" and whether this presents a strategic buying opportunity for long-term investors.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is trending due to a significant capital raise and stock offering, which has sparked mixed community reactions concerning share dilution versus providing essential funding to accelerate FAA certification, manufacturing scaling, and its anticipated 2026 commercial launch. Investors are actively debating the long-term growth potential against current pre-revenue challenges, with many viewing the dip as a strategic entry point given Joby's strong partnerships and lead in the eVTOL market.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is gaining attention following a new partnership with Serbia to introduce air taxi operations and BlackRock's significant stake, which fuels community discussions contrasting its strategic positioning and financial strength against competitors facing capital raises and dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Elevance Health Q4 Earnings Beat Estimates on Increasing Premiums

ELV tops Q4 EPS estimates as premiums grow and Carelon revenues surge, even as medical membership slips and expenses climb.

Centene Expands Palliative Care Access in Ohio Through Tuesday Health

CNC teams up with Tuesday Health to expand palliative care in Ohio, blending in-person and virtual support.

Zacks Research Upgrades Fortress Biotech (NASDAQ:FBIO) to Strong-Buy

Zacks Research upgraded shares of Fortress Biotech from a "hold" rating to a "strong-buy" rating in a research report on Wednesday...

Research Analysts Set Expectations for FBIO FY2025 Earnings

Fortress Biotech, Inc. (NASDAQ:FBIO - Free Report) - Stock analysts at HC Wainwright issued their FY2025 earnings per share estimates for shares of Fortress Biotech in a research report issued to...

Morning Market Brief: From IP Land Grabs to FDA Greenlights, Small-Cap Innovation Takes Center Stage

<ul class="summary-bullets"><li>The FDA’s green light comes after Sentynl Therapeutics, fully owned by Zydus Lifesciences, assumed responsibility for developing and commercializing CUTX-101.</li><li>Cyprium stands to earn tiered royalties on ZYCUBO sales and up to $129 million in potential development and sales milestones from Sentynl.</li><li>Children receiving early treatment with ZYCUBO had a nearly 80% lower risk of death compared with untreated patients.&nbsp;</li></ul>Fortress Biotech, Inc. (FBIO) and its majority-owned unit, Cyprium Therapeutics, announced on Tuesday that the U.S. Food and Drug Administration (FDA) has officially approved ZYCUBO (formerly CUTX-101) for treating Menkes disease in children.The FDA’s green light comes after Sentynl Therapeutics, fully owned by Zydus Lifesciences, assumed responsibility for developing and commercializing CUTX-101 from Cyprium in December 2023.<blockquote>“The approval of ZYCUBO is a pivotal milestone for our company and patients suffering from Menkes Disease, as it is the first and only FDA-approved treatment for this rare, often fatal, pediatric disease.”-Lindsay A. Rosenwald, Chairman, President and CEO, Fortress Biotech</blockquote><h2 class="st-heading-2">Approval And Benefits</h2>The approval also includes a Rare Pediatric Disease Priority Review Voucher, which will be transferred to Cyprium. Additionally, Cyprium stands to earn tiered royalties on ZYCUBO sales and up to $129 million in potential development and sales milestones from Sentynl.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/FBIO">Fortress Biotech stock</a> traded over 12% higher in Tuesday’s premarket. On Stocktwits, retail sentiment around the stock improved to ‘extremely bullish’ from ‘bullish’ territory the previous day. Message volume changed to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_13_083353_png_10f3be8db7.webp" alt="FBIO’s Sentiment Meter and Message Volume as of 07:40 a.m. ET on Jan. 13, 2026 | Source: Stocktwits" width="927" height="102"><figcaption>FBIO’s Sentiment Meter and Message Volume as of 07:40 a.m. ET on Jan. 13, 2026 | Source: Stocktwits</figcaption></figure>Menkes disease is a rare genetic disorder caused by mutations in the ATP7A gene, which disrupt copper absorption and transport in infants. Without treatment, the disease can be fatal, as copper is essential for brain development.&nbsp;<h2 class="st-heading-2">ZYCUBO Efficiency&nbsp;</h2>ZYCUBO, administered as a subcutaneous injection, helps restore copper balance in the body and maintain adequate levels in patients with Menkes disease.Results supporting approval showed that children receiving early treatment with ZYCUBO had a nearly 80% lower risk of death compared with untreated patients. Median overall survival in the treated group was 177.1 months, compared with 17.6 months in the external control group.&nbsp;FBIO stock has gained over 113% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/delta-airlines-stock-falls-2026-guidance-boeing-order/cmUXI2vR44s">Delta Air Lines Stock Tumbles Despite Q4 Earnings Beat – Even A Boeing Order Failed To Lift Confidence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Fortress Biotech logo is displayed on the screen of a tablet.

FBIO Stock Surges 12% Pre-Market After It Wins FDA Approval For Rare Pediatric Menkes Disease

FDA’s ZYCUBO approval also includes a Rare Pediatric Disease Priority Review Voucher, which will be transferred to Cyprium.

Equity

FDA’s ZYCUBO approval also includes a Rare Pediatric Disease Priority Review Voucher, which will be transferred to Cyprium.


Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above Two Hundred Day Moving Average - What's Next?

Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above 200 Day Moving Average - Should You Sell...

Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above 200-Day Moving Average - Here's What Happened

Fortress Biotech (NASDAQ:FBIO) Stock Price Crosses Above 200 Day Moving Average - Here's Why...

Envestnet Asset Management Inc. Sells 98,195 Shares of Fortress Biotech, Inc. $FBIO

Envestnet Asset Management Inc. lessened its holdings in Fortress Biotech, Inc. (NASDAQ:FBIO - Free Report) by 36.7% during the second quarter, according to its most recent 13F filing with the...

Fortress Biotech (NASDAQ:FBIO) Upgraded at Wall Street Zen

Wall Street Zen upgraded Fortress Biotech from a "hold" rating to a "buy" rating in a report on Sunday...

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

FBIO
Fortress Biotech Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest FBIO News

FBIOFortress Biotech Inc